{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:57:23Z","timestamp":1794351443442,"version":"4.9.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clinthera.2025.05.015","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T19:38:30Z","timestamp":1749843510000},"page":"649-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cabotegravir Plus Rilpivirine Injection for Virally Suppressed Persons with HIV-1 infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1629-4723","authenticated-orcid":false,"given":"Erick Wesley","family":"Hedima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John David","family":"Ohieku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahaya Mohammed","family":"Katagum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.05.015_bib0001","series-title":"MSD Manual Professional Edition","article-title":"Human Immunodeficiency Virus (HIV) Infection - infectious diseases","author":"Cachay","year":"2021"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0002","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0003","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3018(18)30132-2","article-title":"Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study","volume":"5","author":"Bavinton","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0004","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0005","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/23259582211009011","article-title":"The promise of improved adherence with long-acting antiretroviral therapy: what are the data?","volume":"20","author":"Scarsi","year":"2021","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0007","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1093\/ofid\/ofz360.1193","article-title":"1329. Experiences and emotional challenges of antiretroviral treatment (ART)\u2014Findings from the positive Perspectives study","volume":"6","author":"De Los Rios","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0008","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3389\/fphar.2017.00831","article-title":"Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment\u2014Clinical points of view and practical considerations","volume":"8","author":"Iacob","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0009","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.16.3.18640","article-title":"Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis","volume":"16","author":"Katz","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002183","article-title":"Patient-reported barriers to adherence to antiretroviral therapy: A systematic review and meta-analysis","volume":"13","author":"Shubber","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0011","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/infdis\/jir370","article-title":"The critical need for alternative antiretroviral formulations, and obstacles to their development","volume":"204","author":"Swindells","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0012","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/00002030-200106150-00015","article-title":"Non-adherence to highly active antiretroviral therapy predicts progression to AIDS","volume":"15","author":"Bangsberg","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0013","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/PPA.S149355","article-title":"Assessment of medication adherence and responsible use of isotretinoin and contraception through Belgian community pharmacies by using pharmacy refill data","volume":"12","author":"Biset","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066860","article-title":"Adherence to antiretroviral therapy and its effect on survival of HIV-infected individuals in Jharkhand, India","volume":"8","author":"Rai","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0015","series-title":"Understanding Fast-Track: Accelarating Action to End the AIDS Epidemic by 2030","year":"2015"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0016","unstructured":"EACS. European AIDS Clinical Society. Guidelines V11.1. EACSociety, https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/ (2022, accessed 12 December 2022)."},{"key":"10.1016\/j.clinthera.2025.05.015_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249515","article-title":"Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV","volume":"16","author":"Teira","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0018","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/QAI.0000000000001896","article-title":"Interest of youth living with HIV in long-acting antiretrovirals","volume":"80","author":"Weld","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0019","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2217\/nnm.12.214","article-title":"Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients","volume":"8","author":"Williams","year":"2013","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0020","unstructured":"Molina J-M, Montes L, Esser S, et al. European phase 3\/3b experience with long-acting cabotegravir and rilpivirine: efficacy, safety, and virologic outcomes, https:\/\/viivexchange.com\/medical\/prot\/eacs-2021-eu-uk-regional-sub-analysis\/ (2022, accessed 21 November 2022)."},{"key":"10.1016\/j.clinthera.2025.05.015_bib0021","unstructured":"Viiv Healthcare. ViiV Healthcare. Vocabria (cabotegravir tablets) and Cabenuva (cabotegravir and rilpivirine extended release injectable suspensions) product monograph. Canada, https:\/\/viivhealthcare.com\/content\/dam\/cf-viiv\/viiv-healthcare\/en_GB\/medicines\/CABENUVA-VOCABRIA-PM-26-Mar-2021.pdf (2020, accessed 12 December 2022)."},{"key":"10.1016\/j.clinthera.2025.05.015_bib0022","unstructured":"Viiv Healthcare. Vocabria summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vocabria-epar-product-information_en.pdf (2021, accessed 12 December 2022)."},{"key":"10.1016\/j.clinthera.2025.05.015_bib0023","unstructured":"Viiv Healthcare. ViiV Healthcare. Cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension (Cabenuva) Prescribing Information. US."},{"key":"10.1016\/j.clinthera.2025.05.015_bib0024","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/COH.0000000000000002","article-title":"Long-acting injectable antiretrovirals for HIV treatment and prevention","volume":"8","author":"Spreen","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0025","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190487","article-title":"Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain","volume":"13","author":"Kerrigan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0027","unstructured":"NCT02938520. A phase III, randomized, multicenter, parallel-group, open-label study evaluating the efficacy, safety, and tolerability of long-acting intramuscular cabotegravir and rilpivirine for maintenance of virologic suppression following switch from an integrase inhibitor single tablet regimen in HIV-1 infected antiretroviral therapy naive adult participants. Clinical trial registration results\/NCT02938520, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02938520 (2022, Accessed November 22, 2022)."},{"key":"10.1016\/j.clinthera.2025.05.015_bib0028","unstructured":"NCT02951052. A phase III, randomized, multicenter, parallel-group, non-inferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting Cabotegravir plus long-acting rilpivirine from current INI- NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed. Clinical trial registration NCT02951052, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02951052 (2022, Accessed November 20, 2022)."},{"key":"10.1016\/j.clinthera.2025.05.015_bib0029","doi-asserted-by":"crossref","unstructured":"Page MJ, Je M, Pm B, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Journal of clinical epidemiology; 134. Epub ahead of print June 2021. DOI:10.1016\/j.jclinepi.2021.03.001.","DOI":"10.1016\/j.jclinepi.2021.02.003"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0030","unstructured":"The Cochrane Collaboration. Review Manager (RevMan), https:\/\/training.cochrane.org\/online-learning\/core-software\/revman (2020, Accessed December 12, 2022)."},{"key":"10.1016\/j.clinthera.2025.05.015_bib0031","unstructured":"Deeks JJ, Higgins J, Altman DG. Chapter 10: analysing data and undertaking meta-analyses, https:\/\/training.cochrane.org\/handbook\/current\/chapter-10 (2020, Accessed December 12, 2022)."},{"key":"10.1016\/j.clinthera.2025.05.015_bib0032","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/QAD.0000000000003085","article-title":"Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy","volume":"36","author":"Mills","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0033","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0034","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0035","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and Rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0036","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0037","unstructured":"HHS Panel on Antiretroviral Guidelines for adults and adolescents. Guidelines for the use of Antiretroviral agents in adults and adolescents with HIV, https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf (2019, Accessed December 12, 2022)."},{"key":"10.1016\/j.clinthera.2025.05.015_bib0038","unstructured":"WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, https:\/\/www.who.int\/publications-detail-redirect\/9789240031593 (2021, Accessed April 1, 2022)."},{"key":"10.1016\/j.clinthera.2025.05.015_bib0039","unstructured":"FMoH. Federal Ministry of Health, https:\/\/www.health.gov.ng\/index.php?option=com_content&view=article&id=129 (2022, Accessed May 20, 2023)."},{"key":"10.1016\/j.clinthera.2025.05.015_bib0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/25787489.2019.1661696","article-title":"Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study","volume":"20","author":"Murray","year":"2019","journal-title":"HIV Res Clin Pract"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0041","doi-asserted-by":"crossref","first-page":"P186","DOI":"10.1186\/1758-2652-13-S4-P186","article-title":"Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-na\u00efve, HIV-1-infected patients in ECHO and THRIVE","volume":"13","author":"Crauwels","year":"2010","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0042","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1473-3099(15)00152-8","article-title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial","volume":"15","author":"Margolis","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0043","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/jac\/dkae480","article-title":"Safety and efficacy of long-acting cabotegravir\/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis","volume":"80","author":"Manalu","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0044","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.664875","article-title":"Safety and pharmacokinetic profiles of long-acting injectable antiretroviral drugs for HIV-1 pre-exposure prophylaxis: A systematic review and meta-analysis of randomized trials","volume":"12","author":"Lazarus","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100303","article-title":"Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women","volume":"21","author":"Bekker","year":"2020","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0047","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/QAD.0000000000003494","article-title":"Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition","volume":"37","author":"Fonner","year":"2023","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0048","doi-asserted-by":"crossref","first-page":"ofab439","DOI":"10.1093\/ofid\/ofab439","article-title":"Efficacy, safety, and durability of long-acting cabotegravir and rilpivirine in adults with Human Immunodeficiency Virus type 1 infection: 5-year results from the LATTE-2 study","volume":"8","author":"Smith","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222229","article-title":"Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis","volume":"14","author":"Cruciani","year":"2019","journal-title":"PLOS ONE"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105653","article-title":"48-Week efficacy and safety of Dolutegravir relative to commonly used third agents in treatment-naive HIV-1\u2013Infected patients: A systematic review and network meta-analysis","volume":"9","author":"Patel","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.clinthera.2025.05.015_bib0051","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:08:45Z","timestamp":1753880925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825001833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0149291825001833"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.05.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cabotegravir Plus Rilpivirine Injection for Virally Suppressed Persons with HIV-1 infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}